Pharming (PHAR) Cash & Equivalents (2019 - 2026)

Pharming's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $52.4 million for Q1 2026.

• Quarterly Cash & Equivalents fell 12.84% year-over-year to $52.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.4 million (down 12.84% YoY) and the FY2025 annual result came in at $145.3 million, up 9587.0% from the prior year.
• Cash & Equivalents was $52.4 million for Q1 2026 at Pharming, down from $145.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $207.3 million in Q4 2022 and bottomed at $1.5 million in Q4 2024.
• A 5-year average of $121.7 million and a median of $132.4 million in 2025 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 106934.94% in 2022, while the deepest fall reached 99.91% in 2022.
• Pharming's Cash & Equivalents stood at $207.3 million in 2022, then plunged by 70.22% to $61.7 million in 2023, then plunged by 97.57% to $1.5 million in 2024, then soared by 9587.0% to $145.3 million in 2025, then plunged by 63.95% to $52.4 million in 2026.
• Business Quant data shows PHAR's Cash & Equivalents at $52.4 million in Q1 2026, $145.3 million in Q4 2025, and $132.4 million in Q3 2025.